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Summary   
Alzheimer’s disease (AD) linked mutations in Presenilins (PSEN) and the Amyloid Precursor Protein 
(APP) lead to production of longer amyloidogenic Aβ peptides. The shift in Aβ length is fundamental 
to the disease; however, the underlying mechanism remains elusive. Here, we show that substrate 
shortening progressively destabilizes the consecutive enzyme/substrate (E-S) complexes that 
characterize the sequential γ-secretase processing of APP. Remarkably, pathogenic PSEN or APP 
mutations further destabilize labile E-S complexes and thereby promote generation of longer Aβ 
peptides. Similarly, destabilization of wild type E-S complexes by temperature, compounds or detergent 
promotes release of amyloidogenic Aβ. Our work presents a unifying model for how PSEN or APP 
mutations enhance amyloidogenic Aβ production, suggests that environmental factors may increase AD 
risk, and provides the theoretical basis for the development of γ-secretase/substrate stabilizing 
compounds for the prevention of AD.  
 
Introduction 
. More than 200 mutations in Presenilin 1 or 2 (PSEN1/2) (Enzyme) (Sherrington et al., 1995) and about 
20 in the Amyloid Precursor Protein (APP) (Substrate) (Goate et al., 1991) strongly support the 
relevance of Aβ (Products) in AD pathogenesis. PSEN1/2 are the catalytic subunits of distinct γ-
secretase intramembrane protease complexes (De Strooper et al., 1998; Wolfe et al., 1999), which 
additionally contain Nicastrin (NCT), Presenilin-enhancer 2 (PEN2) and the Anterior pharynx defective 
1 (APH1) as essential components (De Strooper and Chávez Gutiérrez, 2015).  
Several studies point to long Aβ peptides (≥Aβ42/43) as key players in the initiation of aggregation of 
toxic Aβ-derived species, which ultimately lead to neurodegeneration in AD (Benilova et al., 2012; 
Haass and Selkoe, 2007). Thus, understanding the mechanisms that define the Aβ product length is 
highly relevant for the development of efficient strategies that target toxic Aβ production as part of AD 
disease-modifying therapy. 
γ-Secretases generate Aβ peptides of different lengths from APP and AD causative PSEN mutations 
consistently decrease γ-secretase processivity (number of cuts per substrate molecule) shifting Aβ 
profiles towards longer and thereby more amyloidogenic peptides (Chávez-Gutiérrez et al., 2012; 
Fernandez et al., 2014). Although highly relevant, mechanistic understanding of γ-secretase function is 
very limited. For instance, we do not know how γ-secretase recognizes substrates or what drives the 
sequential cleavage of APP, or how clinical mutations in PSEN lead to the release of longer Aβ peptides. 
Such lack of fundamental insights has allowed controversies about the pathogenic role of PSEN 
(Veugelen et al., 2016) to grow (for discussion see De Strooper and Chavez, 2015).  
Recent structural studies on γ-secretase (Bai et al., 2015a, 2015b) (Figure S1A) reveal that PSEN adopts 
a loosely organized, likely metastable fold, that co-exists in several conformations. These findings are 
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in line with previous low resolution structural analyses (Elad et al., 2014; Li et al., 2014), and with 
FRET-based studies presenting the PSEN/ γ-secretase complex as a dynamic entity (Lleo et al., 2004; 
Uemura et al., 2009, 2010; Wahlster et al., 2013).  
Interestingly, elegant studies depict the rhomboid intramembrane proteases also as intrinsically 
metastable proteolytic systems (Baker and Urban, 2012). Given  that protein stability results from a 
cooperative network of weak interactions, scattered distributed mutations throughout a structure can 
destabilise the entire native fold (Freire, 1999). If PSEN structure, as rhomboids, relied on a network of 
weak interactions throughout the molecule, one could hypothesize that scattered FAD-linked PSEN 
mutations might further “destabilize” its metastable fold and could impact protease function.  
γ-Secretase displays a complex proteolytic activity (Takami et al., 2009). An initial ε-endopeptidase 
cleavage releases the soluble intracellular domain (AICD) and generates a long Aβ fragment (either Aβ49 
or Aβ48) that is successively cut by carboxypeptidase-like γ-cleavages generating shorter Aβn peptides 
(Figure 1A) until Aβ release stops the process. Accordingly, the sequential processing of APP by γ-
secretase involves the formation of distinct enzyme-substrate (E-S) complexes, with each of them 
containing shortened de novo Aβn substrates.  
We hypothesized that the stability of each E-S complex determines the probability of its dissociation 
and thereby the length of Aβ peptides released (Aβ profiles). We thus performed thermo-activity assays 
to quantitatively evaluate the stability of E-S complexes. and find that these become progressively less 
stable with shortening of the  consecutive Aβn substrates. Furthermore, pathogenic PSEN mutations 
consistently destabilize the E-S interaction with APP- and Aβn- substrates, leading to enhanced 
dissociation/release of aggregation-prone, longer Aβ peptides. Similarly, several FAD-causing APP 
mutations  destabilize the E-S complex as well, priming “de novo long Aβ substrates” for dissociation. 
These studies provide a unifying and coherent rationale for how FAD causative mutations affect γ-
secretase processivity. In the context of sporadic AD, it is important that fever-like increase in 
temperature- or exogenous compound- induce destabilization of wild type E-S complexes in vitro and 
in vivo which is sufficient to produce amyloidogenic Aβ peptides. Our work  opens new avenues for the 
discovery of γ-secretase stabilizing compounds (GSSC) as potential therapeutics for AD.  
 
Results 
Progressive destabilization of wild type γ-secretase-APP interactions leads to FAD-like Aβ profiles 
γ-Secretase sequentially cuts APP to generate Aβ peptides of different length (Aβn) (Takami et al., 2009) 
in a process that involves the formation of different E-S complexes (Figure 1A). To investigate the 
relative stabilities of the consecutive E-S complexes, we performed in vitro γ-secretase activity assays 
across a temperature gradient (from 37°C to 65°C), using purified PSEN1/Aph1A γ-secretase and the 
APPC99-3XFLAG substrate. Increments in temperature from 37 to 55.1°C had a modest effect on the 
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initial endopeptidase ε-cleavage (100 ± 15 %) (Figure 1B), but progressively decreased enzyme 
processivity, as indicated by the increase in production of long Aβ peptides (Figure 1C). Specifically, 
quantitative analyses of substrates (Aβ42 and Aβ43) and products (Aβ38 and Aβ40) of the fourth γ-secretase 
catalytic cycle demonstrates the progressive drop in enzyme processivity (Figure 1D). This provides an 
estimate of their “optimum temperature” of production, as well as the temperature at which production 
drops to 50% of the initial levels at 37°C (Tm) (Figure 1E, dotted line). The optimum temperatures for 
Aβ38 (95%CI= 31.9 to 36.9 °C), Aβ40 (95%CI= 38.3 to 40.7 °C), Aβ42 (95%CI= 43.9 to 46.4 °C) and 
Aβ43 (95%CI= 47.8 to 49.6 °C) directly correlate with the length/hydrophobicity of the corresponding 
peptide, and the same conclusion can be derived from the Tm values (Table S1 for Tm ± 95% CI). Our 
data reveal that the E-S complex stability correlates with the substrate length, implying that sequential 
γ-secretase cleavages on APP progressively decrease E-S stabilities and thus increase the probability of 
E-S dissociation and A release. 
Next, we evaluated the temperature dependencies of the γ-secretase ε-cleavage of Notch (Figure 1F) 
(De Strooper et al., 1999). The results (Figure 1G vs. Figure 1B; Tm 95% CI: 57.4°C-59.2°C vs. 
60.0°C-62.4°C, Notch and APP respectively) indicate that although distinct the stabilities of both APP 
and Notch (ε-) E-S complexes are higher than any of the (γ-) E-An complexes (Table S1B). Thus, 
despite strong differences in primary sequence, longer (ε)-substrates display higher stability of E-S 
interactions than seen with shorter (γ) substrates. The relative higher stability of the endo-proteolytic 
cleavage (vs. the γ-cleavages) implies that the associated physiologically relevant signaling cascades 
mediated by -cleaved intracellular protein domains, are relatively more resistant to destabilizing 
perturbations.  
Membrane components stabilize γ-secretase-substrate interactions.  
The evaluation of γ-secretase kinetics in CHAPSO solubilized conditions is a common practice in the 
field. However, compared to cell-based assays (Sato et al., 2003), these conditions promote the 
generation of long Aβ≥42 peptides. Based on the experimental evidence above, we hypothesized that 
detergent extraction, similarly to increasing temperature, might destabilize γ-secretase and therefore 
impair processivity. Hence, we assessed γ-secretase function in CHAPSO resistant membranes (DRMs), 
an alternative and well validated cell-free system for the study of γ-secretase activity (Kakuda et al., 
2012; Matsumura et al., 2014; Szaruga et al., 2015; Wahrle et al., 2002) that yields similar Aβ ratios as 
cell-based assays (Figure S1B-C). We prepared DRMs from five post-mortem human brain samples of 
control subjects. Thermal analysis of ε-endopeptidase activity evaluated by de novo AICD generation, 
revealed no detrimental changes over the 37-65°C temperature interval (Figure 1H), demonstrating the 
stabilizing effect of DRMs on this activity (compare Figure 1H vs. 1B).  In contrast, a mild increment 
in temperature significantly affected γ-secretase processivity (73.2 % ± 10.0 at 40°C; mean of means ± 
SD) (Figure 1I) to a level similar as seen with FAD patient brain samples with further temperature 
increments. s (59.4% ± 2.3 at 45°C and 20.3% ± 5 at 55°C; mean of means ± SD of control brain DRMs  
vs. 44.4% ± 13.6 at 37°C mean of means ± SD of 22 FAD brain DRMs; data for FAD taken from Figure 
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2 in (Szaruga et al., 2015)). These studies demonstrate that the membrane environment shapes Aβ 
profiles by stabilizing the most labile γ-secretase–Aβn complexes and that thermal destabilisation of 
wild type γ-secretase leads to Aβ profiles similar as those seen in FAD. 
 
Aβn substrate length is a determinant for E-S complex stability  
Given that E-S complexes containing relatively long Aβn peptides (n= 45, 43 and 42) are the most labile 
and therefore susceptible to dysregulation, we investigated the conversion of synthetic Aβ46 to Aβ43 
(Figures 2A and 2B) and Aβ45 to Aβ42 (Figures 2D and 2E) by purified wild type enzyme at various 
temperatures. The substrates differ only by one amino acid but display distinct thermal susceptibilities 
(Figure 2B vs 2E), indicating that the relative stability of the E-Aβ46 complex is (two times more stable 
than the E-Aβ45 complex at 51°C, kinetic parameters summarized in Table S2). The importance of 
substrate length for E-S stability is further illustrated by the observation that generation of Aβ43 from 
Aβ46 occurs with similar efficiencies at 37°C and 51°C (Figure 2B and Table S2), while its further 
conversion (in the same reaction mix) to Aβ40 drastically decreases (~82%) at 51°C (Figure 2C). 
Similarly, the Aβ40/Aβ43 and Aβ38/Aβ42 ratios (Figure 2G), which provide estimates for the efficiencies 
of the corresponding cleavages, indicate that γ-secretase cuts Aβ43 more efficiently than Aβ42 already at 
37°C.  
In addition, we investigated the processing of the synthetic Aβ43 by wild type γ-secretase. This peptide 
was cut in a “one-turnover” process, as no Aβ37 was generated in the assay, and its conversion to Aβ40 
occurred very inefficiently already at 37°C (Figure S2) (~0.2% of the efficiency of Aβ45 to Aβ42 at 37°C). 
Remarkably, the efficiency of the Aβ43 to Aβ40 cleavage is higher when a “de novo Aβ43“ (generated 
from Aβ46) is processed than when Aβ43 is given as initial substrate (Figure 2G vs. S2). This suggests 
that pre-established interactions between enzyme and Aβ precursor contribute to the stability of the 
newly generated E- Aβn complex.   
The decreasing stabilities of E-S complexes with peptides <Aβ46 strongly point to a critical Aβ substrate 
length for efficient γ-cleavage processing. Remarkably, the effect of temperature on the catalytic 
efficiencies is explained by decreased proteolytic rates (Vmax) (Table S2) rather than by changes in 
affinity (Km) as will be discussed below. Finally, determination of the apparent substrate equilibrium 
dissociation constant (Kd) revealed a substantial difference between the relative affinities for APPC99 vs. 
Aβ43, Aβ40 and Aβ38 peptides (Figure S3A and Table S4). This provides direct experimental evidence 
that substrate length affects the strength of E-S interactions (Figure 2H). 
 
AD-linked PSEN mutations destabilize γ-secretase–substrate complexes  
We next investigated the effect(s) of AD-linked PSEN mutations on the stability of the γ-secretase 
cleavages. We selected eight pathogenic PSEN1 mutations (P88L, Y115H, M139V, L166P, R278I, 
E280A, G384A and L435F) that impair the ε- endo and γ- carboxypeptidase-like activities to different 
extents (Chávez-Gutiérrez et al., 2012; Saito et al., 2011; Veugelen et al., 2016), differ in age of onset 
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and location throughout PSEN1 (Figure 3A, 3B and Table S3). The R278I and L435F mutations 
additionally affect activation of the γ-secretase pro-enzyme (PSEN auto-proteolysis) and drastically 
reduce levels of the active γ-secretase in cells (Saito et al., 2011; Veugelen et al., 2016). Thermo-activity 
assays using purified wild type or mutant γ-secretase complexes and the APPC99-3XFLAG substrate 
reveal that PSEN mutations consistently shift Tm values for AICD-3XFLAG (Figure 3C), Aβ38, Aβ40 
and Aβ42 production (Figure 3D; upper, middle and lower panels, respectively). Thus, clinical 
mutations consistently destabilize, to different extents, the productive interaction with APPC99 and de 
novo Aβn substrates, relative to the wild type enzyme (Table S1).  
To investigate the underlying cause of the observed destabilization of E-S complexes by PSEN 
mutations we evaluated directly their effects on the intrinsic stabilities of the protease. We subjected 
purified wild type and mutant enzymes to increasing temperatures for 15 minutes, pelleted thermally 
induced aggregates by ultracentrifugation and measuredthe remaining soluble PSEN NTF and CTF 
fractions by immunoblot,. All tested FAD mutations increase aggregation and thus impair the intrinsic 
thermostability of γ-secretase (Figure S4A, 4B). Also the binding of conformational-sensitive 
Nanobodies (Nb4- and Nb28) to γ-secretase is less thermostable with mutant γ-secretases (PSEN1- 
L166P, E280A or G384A) than with wild type complex (Figure S4C, dotted line). The P88L, R278I and 
L435F γ-secretase complexes drastically reduce the endopeptidase activity and produce mostly Aβ43 and 
longer peptides at 37°C (Ohki et al., 2014; Saito et al., 2011; Veugelen et al., 2016). The activities of 
these mutants rapidly decay with increasing temperature (Figure 3C and Figure S5), indicating severe 
destabilisation of the intermediary and initial E-S complexes. This likely explains their inefficient endo- 
and carboxypeptidase activities at normal body temperature. The other PSEN mutations display 
significant, but relatively mild destabilizing effects on Aβ38 production (Figure 3D; upper panel, see 
also the corresponding Tm values in Table S1). Given that Aβ42 is the main precursor of Aβ38, the 
relatively fast decay in Aβ38 production reflects the high probability of Aβ42 release.. The destabilizing 
effects induced by pathogenic mutations become more clear when analyzing Aβ40 and Aβ42 generation, 
which reflects the processing of Aβ43 and Aβ45 substrates, respectively (Figure 3D; middle and low 
panels). The Tm values (Table S1) determined for pathogenic PSEN variants are consistently lower 
than the corresponding wild type values. These findings indicate that the destabilizing effects induced 
by PSEN mutations result in increased E-Aβn complex dissociation rates and hence enhance release of 
longer Aβ peptides, therefore decreasing productive interactions. We note that increased dissociation 
does not necessarily imply a lower affinity for the Enzyme/Substrate interaction (Kd) as will be 
demonstrated below.  The clinical relevance of the AD-mutant induced destabilization of E-S complexes 
is supported by the remarkable correlation between the age of onset for 5 out of 8 PSEN mutations and 
theirdestabilizing effects (Tm) on ε-endopeptidase (Figure 3E) or γ-carboxypeptidase activity (Figure 
3F). Intriguingly,  patients carrying the P88L, R278I and L435F mutations, have a ”delayed” age of 
onset despite their drastic effect on γ- processivity (generation of Aβ≥43). Possibly the extreme low global 
activity of these mutant alleles (generating very small amounts of Aβn) counteracts the deleterious 
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effects that may be associated with the enhanced production of long Aβ peptides. This would explain 
the paradox that the most severe loss of function mutations  result in a later age at onset than the rest  
   
AD-linked APP mutations prime “γ-secretase-Aβ complexes” for dissociation 
Our studies place the E-S complex stabilities central to FAD pathogenesis.  We wondered whether 
pathogenic mutations  in APP would similarly affect these assemblies. We tested T43I-, I45F-, V46F- 
and V46I-APP mutations (Table S3). At the endopeptidase level, three mutations exerted mild 
destabilizing effects while T43I did not differentiate from the wild type (Figure 4A and Table S1). 
When  the E280A-PSEN mutation, which has a mild destabilizing effect (Figure 3C) was used, 
however, endo-proteolytic processing of the V46F and I45F-APP substrates demonstrated additive 
destabilizing effects (Figure 4B and Table S1), indicating converging detrimental effects of APP and 
PSEN clinical mutations. 
We therefore studied in depth the processing of mutant APP substrates in DRMs prepared from insect 
cells expressing wild type γ-secretase (Acx et al., 2014).  AICD and Aβn products were directly 
quantified by MALDI-TOF and MALDI-FTICR mass spectrometry without any enrichment steps 
(Figure S6A-C). Employing this approach allowed us to verify the production of Aβ45 (Figure S6C), 
the stabilizing effect of the membrane-like environment and the relatively weak effect of pathogenic 
mutations in APP on AICD generation (Figure S6D vs. Figure 4A). We also confirmed the previously 
observed shift in the position of the ε-cleavage that favours the Aβ48 -> Aβ42 product line linked to the 
T43I, V46F and V46I substitutions, but not to the I45F variant (Bolduc et al., 2016; Chávez-Gutiérrez 
et al., 2012; Dimitrov et al., 2013) (Figure 4C).  
As shown above, E-S complexes containing Aβn peptides are more prone to destabilization (Figure 4D). 
Beyond 58°C, increased release of the precursor Aβ45 is seen in urea-based gel electrophoresis (Figure 
4J, 55°C). Similar analyses revealed that the T43I substitution increases the thermal susceptibilities for 
the Aβ38, Aβ40, Aβ42 and Aβ43 products (Figure 4E compare to 4D), indicating a mutant-induced 
destabilizing effect on E-S complexes for long Aβ≥43 substrates. In support of this, T43I-mutant Aβ 
profiles show long Aβ products at 37°C and their levels increase with temperature (Figure 4J, Figure 
S6E). As the T43I mutation drastically shifts the position of the ε-cleavage to favor Aβ48 generation 
(Figure 4C), we speculate that the longer Aβ products are Aβ45 and/or Aβ48.  
As previously reported, neither Aβ40 nor Aβ43 products are generated from the mutant I45F-APP 
substrate due to a mutant-induced product-line shift that involves the conversion of Aβ46 to Aβ42 (Bolduc 
et al., 2016). Aβ profiles confirmed the presence of Aβ38 and Aβ42, and showed at 37°C the presence of 
a longer Aβ product with Aβ46 mobility (Figure 4J). Increments in temperature induced progressive 
decrements in Aβ38 (Figure 4F) and increased Aβ42 and Aβ46 levels over the 37-65°C interval (Figure 
4J).   
Finally, the thermo-activity assays with V46F and V46I APP mutations show enhanced Aβ38 and Aβ42 
decays (Figures 4G and 4H, respectively and Figure S6F) and increasing Aβ43 levels at temperatures 
Commented [u1]: I deleted this paragrapg because it does 
nto add additional information, it is in essence confirmatory. 
The essence is the APP mutants and show that they affect 
the complexes in a similar way as the PSEN.   
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above 50°C (Figures 4G and 4H, respectively and Figure S6G), relative to the wild type substrate. 
Thus, these pathogenic substitutions (in particular the V46F mutant) destabilize the γ-secretase-Aβ43 
interaction and may also impair mutant E-S complexes containing Aβ peptides longer than 43 amino 
acids. We expressed transiently the V46F/I substrates in cells and quantified by ELISA secreted Aβ40 
and Aβ43 peptides. As expected, the Aβ40/Aβ43 ratio was strongly reduced confirming the destabilized γ-
secretase-Aβ43 interaction (Figures 4I). Urea based electrophoresis demonstrates enhanced Aβ45 
production from the V46I substrate at 55°C, relative to the wild type DRM reaction (Figure 4J).  
Overall, our data indicate that the T43I, I45F and V46I mutations destabilize the E-S complexes with 
Aβ48, Aβ46 and Aβ45, respectively, leading to dissociation and release of these long Aβ peptides. 
Intriguingly, the V46F mutant destabilizes the ‘wild type’ γ-secretase-Aβ43 complex. The V46F 
substitution drastically shifts the ε-cleavage position to favour the Aβ42 product line (Figure 4C), and 
nevertheless still generates substantial amounts of Aβ40 at 37°C (Figure 4J). This suggests that the 
phenylalanine substitution promotes the alternative cleavage of Aβ48  to Aβ43 (Aβ40 precursor) 
(Matsumura et al., 2014). However, the additional effects of this mutation on docking/presentation of 
the substrate to the catalytic site and/or endopeptidase cleavage specificity (different AICD and therefore 
long Aβ products are generated, Figure 4C) may contribute to the observed effects. Together, our data 
demonstrate that APP mutations located around the γ-cleavage sites impact the stability of E-Aβn 
complexes and consequently enhance product dissociation and the release of long amyloidogenic Aβ by 
a similar mechanism to that proposed for PSEN pathogenic mutations (Figure 4B).  
 
Exogenous factors stabilize or destabilize γ-secretase-substrate interactions 
Previous studies have shown that diverse compounds, referred to as γ-secretase inverse modulators, 
mimic FAD-linked mutations by enhancing Aβ42 generation from the wild type enzyme (Kukar et al., 
2005). In contrast, γ-secretase modulators (GSMs) (Weggen et al., 2001), including endogenous 
metabolites (Jung et al., 2015), enhance protease processivity (Chávez-Gutiérrez et al., 2012; Takeo et 
al., 2014). However, their mechanisms of action have remained elusive.  
We tested three different GSM chemistries (Figure 5A) in γ-secretase thermo-activity assays. As 
expected, the direct γ-secretase modulators GSM A and B and the inverse modulator fenofibrate (GSM 
C) (Kukar et al., 2005) increased and decreased the conversion of Aβ42 to Aβ38 at 37°C, respectively 
(Figure 5B). Most notably, the addition of 10 µM direct GSM to wild type enzyme maintained elevated 
protease processivity (Aβ38/Aβ42) over the 37-55°C interval (Figure 5B), thus apparently stabilizing the 
γ-secretase-Aβ42 interaction. The compound mediated stabilization is also observed to a certain extent 
at the endopeptidase level (AICD production), especially with GSM B (Figure 5C). 
Remarkably, fenofibrate leads to important reductions in AICD production at increasing temperatures, 
which is indicative of a strong destabilizing effect on γ-secretase-APP substrate complexes. Our data 
provide mechanistic insights into the mode of action of therapeutically relevant compounds. 
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Furthermore, these results highlight the possibility that environmental factors affecting the stability of 
the most labile E-S complexes (containing short Aβn) could alter the risk for sporadic AD.  
 
Elevation in body temperature modulates γ-secretase activity in vivo 
Given the observed high thermal susceptibility of the PSEN/γ-secretase activity (Figure 1I), we 
evaluated the effect of elevated temperature in intact cells.  HEK293 cells stably overexpressing human 
APP695KM670/671NL (Swedish mutation) where incubated for 1 hour at 37°C or at 42°C. Cell viability was 
not affected by this short incubation time. ELISA quantification of secreted Aβ showed a significant 
increase of total Aβ produced, especially of Aβ43 (Figure 6A and 6B) and a significant reduction in the 
(Aβ38+Aβ40)/(Aβ42+Aβ43) ratio (products/substrates of the 4th catalytic cycles) at 42°C, relative to 37°C 
(Figure 6C).  
We also induced fever in mice carrying humanized Aβ sequence and the AD-linked Swedish 
(KM670/671NL) APP mutation (Saito et al., 2014) with an injection of 30µg LPS intraperitoneally and 
maintained in a warmed cage (~38.5°C) (Jiang et al., 1999). The treated mice reached a body 
temperature of 40°C (± 0.5°C) 25 minutes post-injection, which was maintained for maximally 2 hours 
(Figure S7). Control animals injected with saline solution and kept at room temperature (RT, ~23°C) 
had body temperatures around 38°C. Quantification of steady-state Aβ levels in plasma by ELISA 
revealed increased total Aβ levels (1.88 fold) in treated vs. control mice and relative increments of 1.51, 
1.94 and 1.82 fold for Aβ38, Aβ40 and Aβ42, respectively (Figure 6D). Accordingly, the Aβ38/Aβ42 ratio 
is lowered in the treated mice (Figure 6E). Other factors than elevated body temperature might have 
contributed to the observed changes in Aβ; however, the results align with the cell culture experiments. 
Thus elevated body temperature augments γ-secretase activity and impairs the efficiency of the 4th γ-
cleavage.  
 
Discussion 
In this study we have shown that clinical mutations in PSEN and in APP destabilize primarily the 
intermediary E-S complexes involved in the sequential processing of APP by γ-secretase, leading to 
enhanced E-S dissociation and thereby release of longer, more amyloidogenic Aβ peptides. We used 
progressive thermal destabilization of the wild type enzyme to evaluate the strength of the different E-
S interactions (Figures 1A and 1E), and demonstrated that increments in temperature mimic the effects 
of clinical AD mutations. Our studies reveal a direct correlation between substrate length and E-S 
complex stability, indicating that each γ-secretase cleavage reduces the stability of the subsequent E-S 
complex and thereby progressively shifts the equilibrium towards dissociation and Aβ release. Direct 
determination of the  Michaelis constants for APP-C99 (Km ~ 400-800 nM (Chávez-Gutiérrez et al., 
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2012; Funamoto et al., 2013)) and for Aβ46, Aβ45 or  Aβ43 substrates (Km ~3 µM, Table S2) as well as 
relative affinities for APP-C99, Aβ43, Aβ40 and Aβ38 (Figure S3A) support this concept.  
We propose that γ-secretase-APPC99 complexes are stabilized by a network of weak bonding interactions 
along the substrate transmembrane domain (TMD) (global fitting). In this scenario the stabilizing 
binding energy depends critically on the area of interacting surface, i.e. on the substrate length, while 
the side chains of the constituting residues are not the main driving force for the formation nor for the 
stabilities of the E-S complexes. This view is supported by the known relaxed γ-secretase substrate 
specificity. However, in sharp contrast, we observed that single amino acid substitutions in APP can 
exert a profound destabilizing effect on E-Aβn, complexes.. These findings imply that the type of 
interactions involved in the stabilization of the initial ε-E-S vs. the consecutive γ- E-S complexes are 
fundamentally different.  
While the nature of the E-S interaction remains unknown, the recent structure of γ-secretase in complex 
with a co-purifying type I transmembrane protein provides interesting insights. As shown in Figure 7, 
a short helical structure anchors the putative substrate to PSEN-NTF, while an unstructured stretch of 
~5 amino acids extends through a wide channel to reach the catalytic residues (Bai et al., 2015b). In our 
view, this co-structure could illustrate how a de novo Aβn product interacts with PSEN before it engages 
in the next catalytic cycle, or is released. In the former case, further unwinding of the N-terminal helix 
must occur in order to fill the S1’-S3’ enzyme pockets (Bolduc et al., 2016) during catalysis(Figure 7). 
This will lead to further destabilization of the anchor helix, which weakens the E-S assembly and 
importantly, confers progressively more significance to other (side chain dependent) interactions along 
the Aβn substrate. This model provides an explanation for why AD-linked substitutions in APP (Aβ42-
46) destabilize γ-secretase-Aβ but not γ-secretase-APPC99 complexes. The presented data indicate that 
Aβ45 and Aβ46 substrates are of a critical length as the following γ-cut drastically reduces the stability of 
the subsequent γ-secretase-Aβ43/42 complexes (Figures 3C and 3F). According to the E-Aβ interaction 
model (Figure 7), this can best be understood by taking into account the fact that unstructured C-
terminal stretches of ~5 amino acids leave N-terminal helical anchors of 13 aa, 12 aa, 10 aa or 9 aa in 
the Aβ46, Aβ45, Aβ43 or Aβ42 peptides, respectively. It appears that an N-terminal helical anchor with at 
least 3 turns (Aβ46) stabilizes E-S interactions and promotes efficient γ- processing.  
Pathogenic PSEN1 mutants, irrespective of their nature or position, destabilize E-S complexes (Figure 
3) and previous work analysing the ε-cleavage show that their effects are not explained by lower 
substrate affinities, but rather by reduced catalytic rates (decreased Vmax, see also Suppl. Table 2). 
Similarly, elevated temperature lowers Aβ processing efficiencies by reducing proteolytic rates. This 
indicates that thermal or mutant- induced destabilization does not affect directly the formation of ‘γ-
secretase-Aβn’ complexes but instead disturbs a subsequent step in catalysis. In agreement, FAD-linked 
mutants in PSEN do not directly affect APPC99 nor Aβn substrate binding to γ-secretase (Figure S3C-
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D). Furthermore, the stabilizing GSMB compound does not change APPC99 nor Aβ43 binding to the wild 
type complex (Figure S3B). Thus, destabilization of the productive E-S interactions is not due to 
alterations in the initial formation of ‘γ-secretase-APP’ complexes, but a consequence of 
thermal/mutant/compound- induced disturbances during the subsequent catalysis.  
Upon E-S formation, the complex can either decompose back to free enzyme and substrate or undergo 
catalysis via a transition state intermediate (E-S* complex), which involves structural rearrangements 
in both the enzyme and the substrate. The γ-secretase proteolytic mechanism likely involves, as 
explained, local helix unwinding prior to cleavage and the resultant backbone break must have a 
destabilizing effect on the remaining helical structure of the subsequent de novo Aβn substrates (Figure 
7).   
Although our knowledge of intramembrane proteolytic mechanisms remains very limited, insights from 
the rhomboids are already very apparent. For instance, the substrate (TMD) helical propensity is likely 
pivotal to the E-S interaction and proteolysis is driven by reaction kinetics, rather than substrate affinity 
(Dickey et al., 2013; Moin and Urban, 2012). We propose that FAD-linked PSEN mutations, or 
increased temperature, disturb the stabilization of the E-S* transition state, promoting non-productive 
dissociation (E-S*→ E+S) or restoration of the E-S state (E-S ← E-S*). In support FAD-linked G384A 
and Delta Exon 9 PSEN mutations decrease the affinity for the transition-state analogue L-685,458 
(Svedruzic et al., 2012). In the case of the APP-CTF substrate, which remains anchored to the 
membrane, a destabilizing effect implies the re-initiation of the proteolytic process (E-S formation). The 
situation is fundamentally different in the case of Aβn substrates, as they are no longer anchored in the 
membrane and their release and dilution into the extracellular milieu makes re-association with the 
enzyme unlikely. In support of our model, others have shown that PSEN pathogenic substitutions 
increase the dissociation rate of the γ-secretase-Aβ42 complex (Okochi et al., 2013).  
It is highly relevant that both APP and PSEN mutants promote the release of relatively long Aβ≥43 
peptides. Thus, while increments in toxic Aβ42 are proposed as drivers of FAD (Potter et al., 2013), our 
findings raise the possibility that even longer Aβ species may have high pathogenic relevance.  
These studies help to understand the mechanism of action of a major class of drug candidate for AD 
therapeutics targeting γ-secretase, i.e. the GSMs (Figure 5). The insights are also relevant to explain the 
inverse correlation between generation of long Aβ42/43 peptides and membrane thickness (Holmes et al., 
2012; Winkler et al., 2012) and the high sensitivity of γ-secretase function to lipid environment changes 
(Holmes et al., 2012; Osenkowski et al., 2008). 
Besides providing fundamental novel insights into the working of γ-secretase, the current report raises 
some additional interesting pathophysiological considerations. The significant changes in γ-secretase 
processivity observed upon mild temperature increments in vitro and in vivo suggest that fever could 
promote amyloidogenic Aβ generation. While further work is needed to investigate the relationship 
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between fever and the occurrence of AD,  it is interesting to notice that carriers of the M694V pyrin 
mutation associated with Familial Mediterranean Fever have a 3-fold higher risk for sporadic early-
onset AD than those with normal alleles (Arra et al., 2006). It is not clarified yet whether this is caused 
by the fever or by other (unknown) effects of this mutation.   
In conclusion, our findings reveal substantial insights into the structural and kinetic γ-secretase 
mechanisms and support a unifying model for AD causative mutations that places generation of longer 
Aβ peptides central in AD pathogenesis. Furthermore, these studies provide a novel conceptual 
framework for investigating γ-secretase (dys)function in sporadic AD, as the demonstrated fragility of 
γ-secretase processivity suggests that mechanisms similar to those underlying FAD may increase the 
risk of sporadic AD in a subgroup of patients (Szaruga et al., 2015). Finally, our findings may guide 
novel efforts to develop safe therapies that target γ-secretase, i.e. the generation of γ-secretase (E-S) 
stabilizing compounds (GSSC) for the prevention and treatment of AD.   
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Figure legends 
Figure 1. Temperature increment induces production of “pathogenic-like” Aβ profiles by wild 
type γ-secretase 
A) Schematic representation of the Enzyme-Substrate (E-S) complexes characterizing the processing of 
APP by γ-secretase. B-E) In vitro activity assays with purified wild type human γ-secretase 
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(PSEN1/APH1a) and APPC99-3xFLAG over a temperature gradient. B) Total AICD-3xFLAG product 
levels analyzed by quantitative western immunoblot (top panel) reveal similar AICD product levels (100 
± 15%) in temperatures ranging from 37 to 55.1°C (white background lower panel). Gaussian fitting 
indicates an optimal AICD production temperature of 44.8°C ± 0.6°C for AICD, (mean ± SE, n>5).  C) 
Aβ profiles resolved in urea gels show enhanced generation of long Aβ peptides in the 37 to 60°C 
temperature range. Loading order: synthetic Aβ peptides (Aβ1-38, Aβ1-40, Aβ1-42, Aβ1-45 and Aβ1-46 
peptides at 1/1/1/0.1/1 molar ratios), purified APPC99 substrate and proteolytic reactions incubated at 
indicated temperatures. (*) Indicates a non-product band, present in the purified APP substrate. D) Aβ38, 
Aβ40, Aβ42 and Aβ43 product levels were quantified by ELISA. Enzyme processivity estimated by the 
Aβ40/43 and Aβ38/42 ratios (substrate/product of the 4th turnover) reveal progressive reductions in the 
corresponding catalytic efficiencies over the 37°C - 51°C range. E) Gaussian fit on temperature-induced 
decays of Aβ38, Aβ40, Aβ42 and Aβ43 products reveal a correlation between the optimal temperature of 
production (interpolated, vertical lines) and peptide length (maximal interpolated Aβ levels adjusted to 
100%;  mean ± SEM, n=4). F) γ-Secretase endopeptidase (ε) and carboxypeptidase-like (γ) cleavage 
sites on transmembrane domains of APP (Takami et al., 2009) or Notch1 substrates (Okochi et al., 2006) 
(black and grey arrows on APP describe the two production pathways shown in figure 1A). G) Thermo-
activity assays with purified wild type γ-secretase show significant differences in thermal susceptibilities 
of the ε-cleavages of Notch-3xFLAG (data in red) (mean ± SD, n=3) vs. APPC99-3xFLAG (data in gray, 
Figure 1B, Pvalue< 0.01). Dotted lines through the manuscript indicate the temperatures at which 
production reaches 50% of their initial levels at 37°C (Tm). H-I) In vitro activity assays using DRMs 
prepared from postmortem human brain samples and APPC99-3xFLAG as substrate were incubated over 
a temperature gradient. H) De novo AICD levels determined by quantitative western blot (top panel) 
show no significant changes over the 37°C-55°C temperature interval (mean of means ± SD, 5 patient 
samples, n ≥2). I) ELISA quantified Aβ38 and Aβ42 products demonstrate that increments in temperature 
lead to progressive impairment in γ-processivity, specifically at the 4th catalytic turnover; (mean of 
means ± SD, 4 patient samples, n=2, One-way ANOVA and Dunnett’s post-test P<0.0001). Previously 
published Aβ38/42 ratios (Szaruga et al., 2015) were determined at 37°C for DRMs prepared from post-
mortem brain samples of 22 FAD patients carrying 9 different PSEN mutations (grey area, mean of 
means ± SD).  
 
Figure 2. Kinetic analyses of the sequential processing of Aβ46 and Aβ45 by wild type γ-secretase  
A, D) Schematics for γ-secretase processing of Aβ46 and Aβ45. B-G) Thermo-activity assays using 
purified γ-secretase and synthetic Aβ46 or Aβ45 as substrates. B) Aβ43 product levels at 37° and 51°C 
was fit with a Michaelis-Menten model (fit ±95% CI), (mean ± SEM , n=4). Notice that part of the de 
novo Aβ43 generated in the reactions is further processed to Aβ40 or Aβ38; thus total Aβ43 generated is 
estimated here as Aβ43+Aβ40+Aβ38.  C) Subsequent conversion of Aβ43 into shorter Aβ40 (or Aβ38, not 
shown) at 37°C or 51°C; (mean ± SEM, n=4). E) Processing of Aβ45 into Aβ42 fit with a Michaelis-
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Menten model (fit ±95% CI)  and F) subsequent cut to Aβ38 at the indicated temperatures (mean ± SEM, 
n=3). Notice that part of the de novo Aβ42 generated in the reactions is further processed to Aβ38; thus 
total Aβ42 is calculated as Aβ42+Aβ38. G) Aβ40/Aβ43 and Aβ38/Aβ42 ratios indicate that Aβ43 is less 
efficiently processed than Aβ42 at 37°C; while both cleavages are strongly impaired at 51°C. Graph 
includes all data points shown in panels C and F (mean ± SEM, t-test, Pvalue< 0.0001). H) Sequential γ-
secretase cuts on APP progressively decrease E-S complex stability and increase the probability of 
dissociation.  
 
Figure 3. AD-linked PSEN1 mutations impair the stability of γ-secretase-substrate complex 
A) Scattered distribution of PSEN residues mutated (red) in FAD. B) 3-D Location of the selected 
PSEN1 mutations (red), except for the R278 which is not resolved in the 3D structure. Catalytic Asp 
residues shown in yellow. B1) lateral and B2) bottom views of PSEN1 structure (brown) with a co-
purifying peptide (grey) (PDB: 5fn2).  C-D) Thermo-activity assays using purified wild type or mutant 
γ-secretase complexes and C99-3xFLAG substrate incubated for 20 min at the indicated temperatures, 
except for the severe P88L mutant which activity was measured after 1 h and its concentration was 10x 
higher. C) Representative immuno-blots showing AICD-3XFLAG levels generated by the different 
protease complexes (top panel). Lower panel shows Gaussian fittings on AICD-3XFLAG product 
levels; (mean ± SEM, n=4) (See Table S1A for Tm ± 95%CI). Null hypothesis (one curve for all data 
sets) rejected; different curves for each data set with P <0.0001. D) Gaussian fittings on ELISA 
quantified Aβ38, Aβ40 and Aβ42 peptides produced by wild type or mutant γ-secretase complexes at the 
indicated temperatures (top, middle and lower panels, respectively); (mean ± SEM, n=4). The relative 
shifts in apparent Tm’s (dotted line) demonstrate the mutant induced destabilizing effects. Different 
curves for each data set in Aβ42 panel (lower) with P <0.0001.  D-E) Apparent Tm ± 95% CI for AICD 
generation and Aβ42 production by mutant enzymes vs. the corresponding age of onset of AD in patients 
(AICD: y = 0.3678*x+ 38.66; ± 95% CI for 5 out of 8 mutants and Aβ42: y = 0.3509*x + 32.48; ± 95% 
CI). Notice that P88L, L435F and R278I are the more severe ‘loss’ of function mutations, and apparently 
show a delayed age of onset (y = 0.8843*x + 7.971, dotted line) (see discussion).  
 
Figure 4. AD-linked APP mutants consistently affect the stability of γ-E-S complexes  
AICD product levels generated in thermo-activity assays from the indicated mutant APPC99-3XFLAG 
substrates and purified A) wild type or B) E280A-PSEN1 mutant γ-secretase complexes. Gaussian 
fittings on de novo AICD-3XFLAG levels (mean ± SEM, n≥3). Different curves for each data set with 
P <0.0001 in (B). (See Table S1A for 95% CI). C-H) MALDI-TOF Mass spectrometry analysis of 
thermo-activity assays using DRMs associated wild type γ-secretase complex and purified wild type or 
mutant APPC99-3xFLAG substrates. C) De novo AICD products at 37°C; (mean ± SEM, n≥4, except for 
I45F mean ± SD, n=2) and D-H) Aβ products generated from the indicated APP substrate over the 
indicated temperature gradient. Aβ product levels are normalized to total endopeptidase activity (total 
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AICD levels); (mean ± SEM, n≥4, except for I45F mean ± SD, n=2). I) Aβ40/Aβ43 ratios determined by 
ELISA in the extracellular media of HEK293 cells transiently expressing wild type or mutant APP 
substrates (n=4, one-way ANOVA and Dunnett’s post-test, *** P≤ 0.001). J) Aβ profiles generated at 
37°C and 55°C resolved in urea-based gels. Synthetic Aβ1-38, Aβ1-40, Aβ1-42, Aβ1-45 and Aβ1-46 peptides 
mixed at 1/1/1/0.1/1 molar ratios were loaded as reference. (*) Indicates a non-product band, present in 
the purified APP substrate. 
 
Figure 5. Evaluation of modulators in γ-secretase thermo-activity assays  
A) γ-Secretase modulators used in the study. B-C) In vitro thermo-activity assays with purified wild 
type γ-secretase and wild type C99-3xFLAG in presence of direct (GSM(A), GSM(B)) or inverse GSM 
C (Fenofibrate). B) Direct modulators enhance γ-cleavage efficiency over temperatures ranging from 37 
to 55°C, relative to DMSO control, (mean ± SEM, n=4). Notice the 2x and 8x increase of the 4th cycle 
with GSM A and GSM B respectively at 37°C. C) The stabilizing/destabilizing effects of GSMs are also 
observed at the first endoproteolytic cleavage of C99. The graph shows Gaussian fitting on AICD 
product levels, (mean ± SEM, n=4; *, ** and **** indicate P values≤ 0.05, 0.01, and 0.0001, respectively).  
 
Figure 6. Elevation in body temperature to fever range modulates γ-secretase activity on A-C) 
cultured cells and D-E) in vivo. A) ELISA quantified Aβ peptides secreted by HEK/Swe APP at 37°C 
and 42°C; B) Secreted Aβ (∑Aβ38+Aβ40+Aβ42+Aβ43) and C) (Aβ38 + Aβ40) / (Aβ42 + Aβ43) (products / 
substrates of the 4th turnovers) ratio demonstrate increased Aβ secretion but decreased processivity at 
42°C, relative to 37°C; (Unpaired t-tests, *p≤ 0.05). D-E) Fever was induced in APP NL female mice 
by intraperitoneal injection of 30 µg of LPS and housing in a pre-warmed cage (see Figure S4). D--E) 
Tukey box-and-whiskers plots for D) ELISA quantified Aβ steady-state levels in plasma and E) the 
Aβ38/42 ratio show increased secreted ∑Aβ (Aβ38+Aβ40+Aβ42) levels and a significant reduction in 
protease efficiency ( 4th catalytic turnover) in the fever group after 100 min fever period, respectively. 
10 control and 10 treated animals were tested, Unpaired two tailed t-tests, *, **, *** and **** indicate 
Pvalues≤ 0.05, 0.01, 0.001 and 0.0001, respectively.  
 
Figure 7. Model for E-S interactions during the multiple turnover processing of APP by γ-
secretase 
PSEN1 structure (Lateral view, brown) (PDB: 5fn2, (Bai et al., 2015b)) with the structure of APPC99 
(purple) (PDB:2LP1, (Barrett et al., 2012)) manually docked in the putative substrate binding (see Figure 
S1 A4). A) C99 or C) Aβn interacts with PSEN before it engages in the next catalytic cycle (E-S*) or is 
released (E+S) (B-D). Unwinding of the N-terminal transmembrane helix (B, D) occurs in order to fill 
the S1’-S3’ enzyme pockets (Bolduc et al., 2016) during catalysis. The progressive shortening of the N-
terminal anchor progressively destabilizes γ-secretase-Aβn complexes shifting the equilibrium towards 
dissociation (Aβn release).  
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Supplementary Figure legends  
Figure S1. A1) 3D structure of the wild type human γ-secretase (PSEN1/APH1a) in complex with the 
putative substrate (PDB: 5fn2, (Bai et al., 2015b)). NCT in green, APH1 in yellow, PEN2 in brown, 
PSEN in beige and the putative substrate peptide in red. A2) lateral and A3) bottom views of the 
membrane core and A4) manual docking of the APPC99 substrate (purple) (2LP1, (Barrett et al., 2012)) 
into the putative substrate binding pocket of the γ-secretase complex. B-C) DRMs prepared from human 
control brain samples tested in in vitro activity assays using 1.5µM purified wild type APPC99-3xFLAG 
substrate. ELISA quantifications and analysis of Aβ product profiles in urea-based gels show enhanced 
γ-secretase processivity (relative to detergent solubilized conditions (Figure 1C, 37°C)). Aβ40 is the main 
product, similar to profiles generated in cell-based assays. The results support a stabilizing effect of the 
membrane environment.  
 
Figure S2. Kinetic analyses of the processing of Aβ43 by γ-secretase. A) Schematic processing of 
Aβ43 to Aβ40 by wild type γ-secretase. B) ELISA quantifications of de novo Aβ40 and Aβ37 generated 
indicate no further processing of Aβ40 to Aβ37. Graph shows Aβ40 product levels generated at 37°C fit 
with a Michaelis-Menten model (mean ± SEM , n=4).  
 
Figure S3. Competition experiments to determine apparent Kd equilibrium affinity values for 
APPC99 and synthetic Aβ43, Aβ40 and Aβ38 peptides. AlphaScreen bead-based proximity assay was 
used to detect the interaction between biotinylated purified WT (A-D) or FAD-linked mutant (C and D) 
γ-secretase complexes (~1 nM) and purified APPC99-3XFLAG substrate (20nM) in the presence of 10 
µM γ-secretase inhibitor X (Calbiochem) (Control), while competing with increasing concentrations of 
untagged C99 substrate (A and C) or synthetic Aβ  peptides (A and D). A, C and D show average ± 
SE, n ≥6. Addition of 10µM GSMB does not change E- APPC99 nor E- Aβ43 binding affinities (B, average 
± SD, n=3). Data was fit to Y=(Top-Bottom)/(1+10^(X-LogIC50)) + Bottom. Note that selected FAD-
linked PSEN variants (L166P, E280A and G384A) display significantly different destabilization effects 
on E-S complexes in our kinetic experiments (Figure 3 C-F).   
Figure S4. Intrinsic stabilities of WT and FAD-mutant γ-secretase complexes.  A-B) WT and AD-
linked protease complexes were heated to 37, 45, 55 or 65°C for 15 min and immediately 
ultracentrifuged to pellet thermally-induced aggregates. The remaining soluble fraction was subjected 
to semi-quantitative SDS-PAGE/western blot and assessed for the levels of PSEN1 NTF and PSEN1 
CTF. A) Quantification of the relative soluble amounts of WT vs AD-linked PSEN1 N-terminal and C-
terminal fragments at the distinct temperatures were used to infer the intrinsic PSEN thermal stabilities 
(n≥6, average ± SE) and B) reveal significant destabilization of the tested pathogenic PSEN1 mutants 
at 55°C when compared to WT protease (Statistical significance: Anova and Dunnett’s post-test, *P≤0.1, 
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**P≤0.01, ***P≤0.001). C) Biotinylated γ-secretase - His-tagged Nb interaction was measured using a 
bead-proximity assay (AlphaScreen). 10 nM biotinylated γ-secretase complexes were pre-incubated 
with 10 nM purified His-tagged nanobody (Nb)4 or Nb28 in the presence of donor and acceptor beads 
for 45 minutes at 30°C. The mix was then subjected to different temperatures over a gradient from 37 
to 70°C for 1h.  γ-Secretase-Nb mixes were all brought back to 25°C prior to Alpha-Screen binding 
detection. Right panel (Nb4) and left panel (Nb 28) show the progressive destabilization of Nb-γ-
secretase complex for wild type and 3 selected FAD mutants (PSEN L166P, E280A and G384A) over 
temperature. A significant shift in the temperature at which the γ-secretase–Nb interaction drops to 50% 
of its initial levels is observed (Figure S4C, dotted line), indicating that mutant protease complexes 
have relatively lower thermostabilities than the wild type (for both Nb-analyses n≥5, average ± SE, 
Temperature vs. normalized signal data was fit to Y=100/(1+(X^HillSlope)/(IC50^HillSlope)), different 
curves for each data set with P<0.0001. 
Figure S5. A) Activity assays performed with purified γ-secretase complexes, containing P88L-, R278I- 
or L435F- PSEN1 pathogenic variants over a temperature gradient. Urea–based gel electrophoresis 
confirms production of only long Aβ peptides (≥Aβ43) from these protease complexes at 37°C (Ohki et 
al., 2014; Saito et al., 2011; Veugelen et al., 2016).  
Figure S6. MS-based MALDI mass spectrometry allows detection (and relative quantification) of the 
two (or more) alternative ε-cleavage products (AICD50 and AICD49) as well as the Aβ38, Aβ40, Aβ42, 
Aβ43 and Aβ45 peptides, substrates and products of the 3rd and 4th γ-secretase turnovers in both amyloid 
product lines. A-B) Illustrates the linear mode (low resolution) MALDI-TOF MS analysis of the AICD 
and Aβ peptide products generated by DRM-associated wild type γ-secretase from purified wild type 
APPC99-3XFLAG in 20 min, at 37°C (upper panel) or 60°C (lower panel) in the presence or absence of 
the active site inhibitor X (Inh X). “No C99” denotes a no-substrate control reaction. C) Illustrates high 
resolution MALDI FT-ICR mass spectra of wild type Aβ1-45 originating from APPC99-3XFLAG in 20 
min at 37°C or 60°C. The high resolution analysis allows the monoisotopic separation of the target 
peptide with a mass accuracy of ~1ppm calculated from the base peak (most intensive isotope, marked 
with a star *). “No C99” denotes a no-substrate control reaction. Please note that relative reductions in 
Aβ38, Aβ40 and Aβ42 product levels are accompanied by increases in Aβ43 and Aβ45. E) MALDI-TOF 
MS analysis of the AICD products generated by (insect cells-derived) DRM-associated wild type human 
γ-secretase from either purified wild type or mutant APPC99-3XFLAG at different temperatures. Note 
the increased temperatures compared to the experiments performed with detergent-solubilized enzyme 
(Figures 1B and 4A).  Graphs show mean ± SEM, n=4. D) DRMs prepared from insect cells expressing 
the wild type human γ-secretase were used as source of enzyme and tested in in vitro thermo-activity 
assays using purified mutant T43I APPC99-3xFLAG substrate. Aβ profiles resolved in urea gels show 
enhanced generation of long Aβ peptides in the 37 to 60°C temperature range. Loading order: synthetic 
Aβ peptides (Aβ1-38, Aβ1-40, Aβ1-42, Aβ1-45 and Aβ1-46 peptides at 1/1/1/0.1/1 molar ratios), purified T43I 
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APPC99-3xFLAG substrate and proteolytic reactions incubated at indicated temperatures. F-G) Aβ 
product signal intensities extracted from low resolution MALDI TOF data, generated from wild type or 
mutant APP substrates at the indicated temperature and normalized to total endopeptidase activity (total 
AICD levels); mean ± SEM, n=4. 
Figure S7. Elevation in body temperature to fever range modulates γ-secretase activity in vivo. A) Fever 
was induced in APP NL female mice by intraperitoneal injection of 30 µg of LPS (syringe) and housing 
in a pre-warmed cage for 100 min. Control mice were kept at room temperature (RT, 22-24°C) and 
subjected to the same handling. Mice body temperature was monitored by rectal measurements every 
25 min. At the end of the experiment mice were sacrificed in CO2; mean of means ± SD from 10 control 
and 10 treated animals.  
 
STAR Methods 
Contact for reagent and resource sharing 
Further information and requests for resources and reagents should be directed to and will be fulfilled 
by the Lead Contact, Lucía Chávez Gutiérrez (Lucia.ChavezGutierrez@cme.vib-kuleuven.be). 
 
Antibodies and reagents  
Antibodies were purchased as follows: anti-FLAG M2 from Sigma, Alexa 790 Goat anti-Mouse 
IgG from Invitrogen, 82E1 against human Aβ (N-term) from IBL, biotinylated anti-mouse IgG 
from Vector Laboratories and streptavidin-HRP from GE Healthcare. ELISA antibodies and γ-
secretase modulators were obtained through collaboration with Janssen Pharmaceutica NV, 
Beerse, Belgium: JRF AB038 for Aβ1-38, JRF/cAb40/28 for Aβ1-40, JRF/cAb42/26 for Aβ1-42 
and detection antibody JRF/AbN/25 against the N-terminus of Aβ. Elisa kit against amyloid β (1-
43) (FL) was purchased from IBL, AlphaLISA Detection Kit against amyloid β (1-40) was 
purchased from PerkinElmer. Fenofibrate was purchased from Sigma Aldrich. Synthetic β-
Amyloid 1-38, 1-40, 1-42, 1-43 and 1-46 were purchased from rPeptide and 1-45 from Anaspec. 
β-Amyloid 1-43 used as standards in ELISA was from IBL and 1-40 standard in AlphaLISA from 
PerkinElmer. γ-Secretase inhibitor X purchased from Calbiochem. Complete protease inhibitor 
tablets were purchased from Sigma-Aldrich. All reagents for MALDI-Mass Spectrometry used in 
this study were of HLPC grade. Acetonitrile (ACN) and trifluoroacetic acid (TFA), were 
purchased from Merck (Darmstadt, GER). Milli-Q water (ddH2O; Millipore) was prepared in-
house. Sinapinic acid (SA; Cat. No.201345) and MALDI-MS protein calibration standard I (Cat. 
No.206355) were purchased from Bruker Daltonics (Bremen, Germany). 
Expression and purification of wild type APPC99, wild type and mutant APPC99-3xFLAG 
and wild type Notch-based 3xFLAG substrates  
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Human wild type and mutant (T43I (T714I), I45F (I716F), V46F (V717F) and V46I (V717I)) 
APPC99-3xFLAG and Notch-based (Notch-3xFLAG) substrates were expressed in COS1 or 
HEK293 cells. Briefly, cells were transiently transfected with pSG5-APPC99-3xFLAG (wild type 
or mutant) or pSG5-Notch-3xFLAG vector. Before collection, cells expressing C99-3xFLAG 
were treated overnight with 10 µM GM GM6001 inhibitor (Sigma) to prevent its conversion to 
C83-3xFLAG. Cells were harvested and resuspended in 50mM Tris-HCl pH 7.6, 150 mM NaCl, 
1% Nonidet P-40, 1X PI and incubated on ice for 1 h. Membrane-solubilized protein fractions 
were obtained by ultracentrifugation at ~200000g for 20 min. Wild type APPC99 substrate with a 
PreScission Protease cleavage site and 3X-FLAG-tag (APPC99 –PPS-3X-FLAG) at the C-terminus 
was cloned in the pAcAB4 vector and expressed in Hi5 insect cells. Cells were collected 48-72 h 
post infection and resuspended in 50mM Tris-HCl pH 7.6, 150 mM NaCl, 1X PI. Total 
membranes were prepared and rinsed twice in 1x TBS, 1M NaCl and complete protease inhibitor 
mixture. Membranes were solubilized ON in 1x TBS, 1% n-dodecyl β-d-maltopyranoside (DDM; 
Anatrace) and 1X PI at 4⁰C. Membrane-solubilized protein fractions were obtained by 
ultracentrifugation at ~200000g for 45 min. 
FLAG-tagged recombinant substrates were purified by immunoaffinity chromatography using the 
anti-FLAG M2-agarose beads (Sigma), according to the manufacturer’s protocols. All substrates, 
except for the APPC99 –PPS-3X-FLAG, were eluted in 100mM glycine HCl, pH 2.7, 0.25% n-
dodecyl β-D-maltoside (Sigma) and immediately neutralized to pH 7 by the addition of Tris-HCl, 
pH 8.0. Digestion with GST-tagged PreScission protease eluted APPC99 –PPS-3X-FLAG in 
25mM Pipes, 150mM NaCl, 0,02% DDM, 0,5mM EDTA and 1mM DTT. Removal of the 
PreScission protease was done by immunoaffinity pulldown using Glutathione Sepharose 4B (GE 
Healthcare). Purity was assessed by SDS-PAGE and Coomassie staining (InstantBlue Protein 
Stain, Expedeon). 
 
Expression and purification of γ-secretase complexes  
Human wild type or mutant (P88L, Y115H, M139V, L166P, R278I, E280A, G384A, L435F) 
PSEN1, NCT-GFP, APH1AL and PEN2 cDNAs were cloned into the pAcAB4 transfer vector 
(BD Biosciences). Co-transfection of the transfer vector (containing the heterologous genes) and 
flashBacGoldTM DNA (Oxford Expression Technologies) in Sf9 cells allowed homologous 
recombination and production of baculoviruses bearing the four essential subunits of the γ-
secretase complex. A PreScission Protease cleaving site (LeuGluValLeuPheGln/GlyPro) and 
GFP were cloned at the C-terminal site of NCT. Protease complexes were expressed in Hi5 insect 
cells. Infected Hi5 cells were collected at 72 h post infection and lysed in 2% CHAPSO (Anatrace) 
buffer (25 mM Pipes pH 7.4, 300 mM NaCl, 5% Glycerol, 1X Protease inhibitors (PI). Affinity 
purification was carried out using a high affinity anti-GFP nanobody covalently coupled to 
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agarose beads (NHS-activated beads, GE Healthcare) in a 3:1 ratio (mg:ml). PreScission protease 
cleavage between NCT and GFP eluted untagged γ-secretase complexes (buffer composition: 25 
mM Pipes pH 7.4, 150 mM NaCl, 0.5% CHAPSO, 5% Glycerol). Finally, removal of the GST-
tagged PreScission protease by immunoaffinity pulldown using Glutathione Sepharose 4B (GE 
Healthcare) was performed and the purity of γ-secretase complexes was assessed by SDS-PAGE 
and Coomassie staining (InstantBlue Protein Stain, Expedeon). 
Subjects  
Human cortical specimens were obtained throughout collaboration with Queen Square Brain 
Bank for Neurological Disorders at University College London. All of the samples came from 
brains that were removed and placed in -80°C within 42 hours postmortem. Samples were 
collected following protocols approved by respective ethical boards and written legal consents for 
the use of organs for medical research are available for each patient. All human protocols were 
approved by Medical Ethics Committee UZ KU Leuven, Belgium.   
Detergent resistant membrane preparation from insect cells and human brain samples 
CHAPSO detergent resistant membranes (DRMs) were prepared from Hi5 insect cells 
overexpressing PSEN1/APH1A γ-secretase complexes (WT or mutant complexes containing 
PSEN1 pathogenic mutations P88L, Y115H, M139V, L166P, R278I, E280A, G384A or L435F) 
or human brain frontal cortices (after careful removal of leptomeninges and blood vessels). In 
case of human brain samples, around 200 mg blocks of tissue were homogenized in ~ 10 volumes 
of 10% sucrose in MBS buffer (25mM MES, pH 6.5, 150mM NaCl) containing 1% CHAPSO 
(Sigma) and 1X PI. DRMs from insect cells were prepared from total membranes (200 ml Hi5 
cell culture). Membrane pellets were homogenized in ~ 2.5 ml of 10% sucrose in MBS buffer 
containing 1% CHAPSO (Sigma) and protease inhibitors. Brain or cell membrane homogenates 
were mixed with equal volume of 70% sucrose in MBS buffer, 4 ml was placed at the bottom of 
an ultracentrifuge tube (Beckman, 344059) and successively overlaid with 4 ml of 35% sucrose 
(MBS) and 4 ml of 5% sucrose (MBS). Samples were centrifuged at 39,000 rpm for 20 h at 4°C 
on a SW 41 Ti rotor (Beckman). After centrifugation the DRM fraction (interface of 5%/35% 
sucrose) was carefully collected, rinsed in 20mM PIPES, pH 7, 250mM sucrose, 1M EGTA and 
recentrifuged twice (100,000 g, 60 min, 4°C). The resultant pellet was resuspended with above 
buffer and stored at -80°C until use. 
Evaluation of γ-secretase activity in cell culture 
To assess the effect of elevated temperature on Aβ production, HEK293 cells stably expressing 
human APP695 KM670/671NL (Swedish) were plated at 1X106 cells/9 cm2 well; after 24h, cells 
were washed with serum-free media and medium refreshed (1ml). Cells were immediately placed 
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at 37 or 42°C and after 1h incubation the extracellular media was collected for Aβ ELISA analyses 
and cell viability was assessed (trypan blue staining). To determine the effects of mutations in 
APP on Aβ production, wild type HEK293 cells were transfected with pSG5-based expression 
vectors bearing wild type or mutant APPC993xFLAG cDNAs. At 36h post-transfection, cells were 
rinsed and medium refreshed. Extracellular media was collected after 4h incubation at 37°C. For 
all experiments, cells were cultured in Dulbecco’s modified Eagle’s medium/F-12 containing 
10% fetal bovine serum and sAβ were analysed by MSD ELISA. 
γ-Secretase in vitro thermo-activity assays 
Proteolytic reactions were performed using purified ~10nM PSEN1/APH1A γ-secretase 
complexes and purified recombinant FLAG tagged substrates in 0.25% CHAPSO, 2.5% DMSO 
(or 10µM GSM, 100µM Fenofibrate), 0.1% Phosphatidylcholine, 150mM NaCl and 25mM 
PIPES over a temperature gradient ranging from 37°C-65°C for 20 min (except for the severe 
P88L mutant protease which activity was measured after 1h incubation and with 10X more 
enzyme). Enzyme mixes (containing all components except the substrate) and substrate dilutions 
were pre-incubated separately at the indicated temperatures for 10 min. After pre-incubation, 
substrate was added to the enzyme mix and proteolysis proceeded for 20 min or 1h (P88L). Final 
substrate concentrations in assays were 1.75 µM C99-3xFLAG or 2µM Notch-3xFLAG unless 
otherwise indicated.  
γ-Secretase thermo-activity assays using Aβ43, Aβ45 or Aβ46 synthetic peptides as substrates and 
purified wild type γ-secretase were carried out as indicated above with the following 
modifications: synthetic Aβ peptides were diluted in DMSO and proteolytic reactions were 
incubated for 1 hour (Aβ45 or Aβ46) or 4h (Aβ43) at the indicated temperatures.  
Thermo-activity analyses using DRMs as source of enzyme were performed similarly, but 
reactions contained 0.6 µg/µl or 1 µg/µl protein for DRMs prepared from Hi5 insect cells 
overexpressing γ-secretase components or human brain samples, respectively. Assays were 
carried out for 20 min for DRMs derived from insect cells or 4h for DRMs prepared from human 
brain samples in saline MBS buffer (150mM NaCl, 25mM MES), 0.1% DMSO, 1mM EGTA and 
protease inhibitors (Complete, ROCHE) with purified substrates at saturating concentrations. 
Temperature gradients ranging from 37°C-60°C and 60°-80°C were set for DRM analyses. All 
thermo-activity assays were performed on a PCR thermocycler (Biorad T100). 
Quantification of γ-Secretase endopeptidase activity  
γ-Secretase endopeptidase products (ICD-3XFLAG) generated in the proteolytic assays were 
quantified by SDS-PAGE western immunoblot and/or MALDI-MS (see MALDI-MS analysis). 
In the first case, reactions were mixed with one volume of methanol-chloroform (1:2, v/v) to 
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remove hydrophobic molecules (lipids, substrate and membrane proteins) and aqueous fractions 
containing ICD products were analyzed by SDS-PAGE western immunoblot using anti-FLAG 
M2 antibody and quantified with Odyssey infrared imaging system.  
Quantification of Aβ production by ELISA 
Aβ38, Aβ40 (except for quantification of Aβ40 from proteolytic reaction using Aβ43 as substrate, 
which was quantified using AlphaLISA Detection Kit from PerkinElmer according to 
manufacturer’s protocol) and Aβ42 product levels were quantified on Multi-Spot 96 well plates 
pre-coated with anti-Aβ38, Aβ40, and Aβ42 antibodies obtained from Janssen Pharmaceutica using 
multiplex MSD technology. MSD plates were blocked with 150 µl/well 0.1% casein buffer for 
1.5 h at room temperature (600 rpm) and rinsed 5 x with 200 µl/well washing buffer (PBS + 
0.05% Tween-20). 25 μl of SULFO-TAG JRF/AbN/25 detection antibody diluted in blocking 
buffer was mixed with 25 μl of standards (synthetic human Aβ38, Aβ40, Aβ42 peptides) or reaction 
samples diluted in blocking buffer and loaded  50 μl per well. For the quantification of Aβ peptides 
generated in activity assays using synthetic Aβ43, Aβ45 and Aβ46 as substrates, reactions with no 
enzyme were loaded to determine background levels. After overnight incubation at 4°C plates 
were rinsed with washing buffer and 150 µl/well of the 2x MSD Read Buffer T (tris-based buffer 
containing tripropylamine, purchased from Meso Scale Discovery) was added. Plates were read 
immediately on MSD Sector Imager 6000. Aβ43 product levels were quantified with β-Amyloid 
1-43 kit from IBL according to manufacturer’s instructions. Aβ38, Aβ40 and Aβ42 product levels 
in proteolytic reactions using DRMs were analyzed by MALDI-MS (see below). 
Detection of Aβ product profiles in Urea gels  
Aβ-products were analyzed in urea-based bicine/tris SDS–PAGE (Wiltfang et al., 2002). Gel 
thickness was kept at 0.75mm and the composition of the separation gel was as follows:  8M 
Urea, 11% T/5% C polyacrylamide, 0.4M H2SO4, 0.25% SDS, pH=8.1. Electrophoresis was 
conducted at constant 100V for around 2h, after that, gels were transferred to a PVDF membrane 
and western immunoblot with 82E1 antibody, biotinylated anti-mouse IgG and streptavidin-HRP 
was performed. Signals were detected using ECL chemiluminescence with Fujifilm LAS-3000 
Imager. 
AlphaScreen substrate competition assays to assess γ-Secretase-Substrate relative affinities 
Acceptor M2-anti-FLAG beads (0,1 µl/reaction) and purified APPC99-3XFLAG (20 nM final 
concentration in assay) were pre-incubated with increasing concentrations of purified untagged 
APPC99 substrate or synthetic Aβ peptides in buffer with DDM (0,04% final concentration in 
assay) for 1h at 37⁰C (Mix 1, M1). Simultaneously, Mix 2 (M2) containing purified biotinylated 
γ-secretase (1 nM final concentration in assay), Inhibitor X (10 µM final concentration in assay), 
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0.1% Phosphatidylcholine, 0.005% Lauryl Maltose Neopentyl Glycol (LMNG) and donor beads 
(0,1 µl/reaction) was prepared and pre-incubated at 37⁰C. Competition assays started with the 
mix of M1 and M2, binding signals were detected after 4 h incubation in dark at 37⁰C. The assay 
was done in 384-well OptiPlates (PerkinElmer) in a final volume of 25 µl. Biotinylation of γ-
secretase was done by incubation of purified γ-secretase with a 30 fold molar excess of EZ-link 
Sulfo-NHS-SS-Biotin reagent (ThermoFisher Scientific) during 2 h on ice. Remaining free biotin 
reagent was removed by dialysis using dialysis units (Spectra/Por Float-A-Lyzer G2) with a 
100kDa cutoff. Apparent equilibrium dissociation constants (Kd) for APP C99-3XFLAG and 
synthetic Aβ43, and Aβ40 substrates using wild type human γ-secretase (PSEN1/APH1a) were 
derived by nonlinear curve fitting (Y=(Top-Bottom)/(1+10^(X-LogIC50)) + Bottom) using 
GraphPad Prism 7.01 software. According to Cheng and Prusoff equation for competitive binding 
(Cheng and Prusoff, 1973), apparent Kd equilibrium= IC50/(1+([L]/Kd)), where L is the APPC99 
substrate; when Kd is significantly higher than the concentration of substrate, the value for [L]/Kd 
approaches zero and the apparent Kd approximates the IC50 in the competition binding assay.    
Assessment of intrinsic thermostabilities of wild type and FAD-linked mutant γ-secretase 
complexes 
Purified PSEN1/APH1A γ-secretase complexes containing wild type or pathogenic PSEN1 
(P88L, Y115H, M139V, L166P, R278I, E280A, G384A or L435F) were diluted to similar protein 
concentrations in 150mM NaCl, 25mM PIPES and 0.5% CHAPSO and incubated for 15 min at 
37, 45, 55 and 65°C. Next, in order to separate the heat-aggregated fraction from the remaining 
soluble enzyme, samples were centrifuged for 20 min at ~200000 g.  The supernatant was 
collected and subjected to SDS-PAGE electrophoresis. Western immunoblot was performed with 
anti- PSEN1-NTF and PSEN1-CTF antibodies to assess the gradual heat-induced aggregation of 
the distinct protease complexes.  
Determination of relative thermostabilities for wild type and FAD-linked mutant γ-
secretase complexes using Nanobodies 
Recombinant antibodies from Camelidae (VHHs, Nanobodies (Nbs)) are conformational-
sensitive probes that display relatively high thermostabilities (Ewert et al., 2002; Olichon et al., 
2007). These features make them suitable tools to investigate thermal-induced unfolding of their 
targets. We used two conformational anti-γ-secretase Nbs: Nb4 binds to a not yet fully 
characterized non-linear epitope in the multimeric complex (1% CHAPSO), but does not bind to 
TX-100 dissociated subunits. Nb28 binds to a conformational epitope in the NCT subunit. 10 nM 
purified, biotinylated wild type or mutant γ-secretase complexes were pre-incubated with 10 nM 
purified, His-tagged Nb4 or Nb28 in the presence of Streptavidin coated donor beads and Ni-
chelate acceptor beads in assay buffer (25 mM Pipes, 150 mM NaCl, 0.5% CHAPSO and 0.1% 
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BSA) for 45 minutes at 30°C. The mix was split over 8 different PCR tubes (25µl/tube), which 
were incubated at the indicated temperatures for 1h, followed by 10 minutes incubation at at 25°C 
(thermal equilibration prior to binding detection). Temperature gradients ranging from 30°C-50°C 
and 50°-75°C were set on a Biorad T100 PCR thermocycler. Next, 20µl sample was transferred 
to a 384-well OptiPlate (PerkinElmer). Upon illumination, a luminescence signal at 620 nm was 
detected by the EnVision plate reader (PerkinElmer). 
MALDI-MS sample preparation and analysis of γ-secretase products 
Sample preparation for MALDI-TOF MS in vitro Aβ/AICD profiling was performed as follows: 
A total volume of 15 µl of in vitro γ-secretase activity reactions were mixed with 15 µl SA (38 
mg/mL in water/ACN/TFA 40/60/0.2 (v/v/v)) without any additional purification or enrichment 
steps. Thereafter, 1 µl (8 technical replicates) of the matrix-analyte mix was applied on top of the 
thin SA layer using the dried droplet preparation (double layer) and air dried. All mass spectra 
were acquired on an UltrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker Daltonics) 
equipped with a 2 kHz SmartbeamTM laser using the AutoXecute function of the FlexControl 3.4 
acquisition software: Briefly, each spectrum was acquired in linear positive mode within the mass 
range of m/z 2,500 to 20,000 with a low mass gate at m/z 2,000. 5,000 laser shots were 
automatically accumulated for each sample by random walk. Mass spectrometer parameters were 
balanced for optimal resolution and sensitivity in the Aβ peptide mass range (4-5 kDa). 
Subsequently, protein mass spectra were baseline-subtracted and externally calibrated in Flex 
Analysis 3.4 (Bruker Daltonics) using the protein calibration standard I (Bruker Daltonics). 
Average MALDI MS profiles were generated from eight single spectra using ClinProTools 3.0 
software (Bruker Daltonics) (CPT). The following modified CPT processing parameters 
((Munteanu B. and C. Hopf, 2016)) were used: Resolution 1000: Convex Hull baseline 
subtraction with a baseline flatness value of 0.75: Mass Range (m/z) 2,500-20,000: Spectra were 
recalibrated, allowing a mass tolerance of 500 ppm matched on 30 % of the peaks. Not 
recalibrated spectra were excluded. Peak picking was performed on total average spectra (based 
on intensity calculation and zero level integration type) using an intensity signal to noise (S/N) 
threshold > 5. 
 
High Resolution MALDI FT-ICR 
Monoisotopically resolved protein signals were recorded using a 7T Solarix XR MALDI FT-ICR 
mass spectrometer equipped with an Apollo II dual MALDI/ESI ion source and a 2 kHz 
Smartbeam II laser (Bruker Daltonics). Sample preparation for MALDI-FT-ICR measurements 
was done as previosly described. Data were acquired in positive ion mode from 150 to 10,000 m/z 
using magnitude mode and 4M data size with a resolving power of 390,000 at m/z 400 and 
~40,000 at m/z 4,000, respectively, and a free induction decayof 2.9 s. The following tuning 
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parameters were used; Ion transfer (Funnel 1 100 V; Skimmer 1 45 V; Funnel RF Amplitude 150 
Vpp; Octopole 2 MHz, RF Amplitude 350 Vpp; RF Frequency 1.4 MHz, 1200 Vpp; Transfer 
Optics Time of Flight 2.9 ms, Frequency 1 MHz, FR Amplitude 350 Vpp; Q1 Mass 4,000 m/z. 
Excitation Mode (Sweep Excitation; Sweep Step Time 15 µs), Ramped Power Excitation 
(Continuous, 14-28 %). A total accumulation of 100 scans was done. Before measurement the 
MALDI-FT-ICR MS was externaly calibrated using the Bruker protein calibration mix I 
containing the following components (Ubiquitin [M+H] + m/z 8560.623989, Insulin [M+H]+ m/z 
5730.608146 and the signal corresponding to the doubly charged Ubiquitin [M+2H]2+ m/z 
4280.815633). Spectra recalibration was done by performing a one-point intenal recalibration on 
the most promiment amyloid beta signal in the analysis and was done using the software Data 
Analysis 4.4 (Bruker Daltonics). Computational analysis and mass matching were performed 
using the Bruker Biotools 3.2 SR5 (Bruker Daltonics) software. 
Elevation of body temperature in mice 
Eleven to sixteen-week-old female APP NL mice were injected intraperitoneally with 30 µg of 
LPS (Sigma-Aldrich) in 500 µl of sterile saline. Age-matched control were treated simultaneously 
with saline only. Mice injected with LPS were immediately placed in cages preheated with a 
heating pad, a red light lamp and a 60 W bulb to ~ 38.5°C. Mice core body temperature raised 
within 25 min to 40°C (± 0.5°C) and then maintained at 39.9°C (± 0.6°C) for 100 min (Figure 
S5). Mice rectal temperature was monitored every 25 min (see Figure S4). Control mice were 
kept at room temperature (RT, 22-24°C) and subjected to the same handling. At the end of the 
experiment mice were sacrificed in CO2 and decapitated. Collected blood was used to isolate 
plasma by 10 min centrifugation at 1500 g. Aβ38, Aβ40, and Aβ42 steady-state levels in plasma 
were analyzed by ELISA (multiplex MSD technology). The protocol was approved by ethical 
committee of KU Leuven (project number: 142/2015). 
Statistical analysis 
All statistical analysis was performed using GraphPad Prism software. Statistical evaluation of 
MALDI-MS data of drug/temperature effects on γ-secretase Aβ/AICD activity, were done on total 
ion count normalized (CPT) average mass spectra. Briefly, eight single mass spectra were 
processed as described above, and average intensity values (arbitrary units) were extracted for 
defined Aβ peptides or AICDs within a mass tolerance window of 500 ppm and transferred to 
GraphPad Prism software for further analysis and visualization. Linear MALDI TOF MS signals 
corresponding to amyloid beta were confirmed by high resolution MALDI-FT-ICR analysis with 
a mass accuracy <<5ppm. 
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